Phase II study of doxorubicin and thalidomide in patients with refractory aggressive fibromatosis

Conclusions ADM plus THA was well-tolerated and effective as a first-line treatment for patients with refractory AF. However, patients with hypoalbuminemia at baseline had inferior clinical outcomes, and further studies are needed to investigate this issue.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research